DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE

“预防胜过治疗”，这是传染病疫苗背后的动机。目前的流感疫苗需要帮助，因为它们只在短期内有效，特别是对老年人和患有慢性病的患者。此外，必须每年准备新的疫苗，以预防新的流感病毒株。因此，对开发新的免疫增强佐剂以改进现有流感疫苗的需求很大。我们的合同支持开发一种新的疫苗佐剂Fos47，它可以提高疫苗的耐用性和动物模型的交叉保护。疫苗佐剂Fos47的保护效果将在流感病毒攻击模型中进行评估，以确定最佳剂量、免疫路线和免疫频率。该疫苗佐剂将大规模制备，以启动人体临床试验。

“Prevention is better than cure”, is the motive behind the vaccines for infectious diseases. Current vaccines for influenza need help as they are only effective for short durations, particularly in elderly individuals and patients with chronic diseases. Also, new vaccines must be prepared yearly to protect against new strains of influenza virus. Thus, there is substantial demand for the development of new immune boosting adjuvants to improve existing influenza vaccines. Our contract supports the development of a new vaccine adjuvant, Fos47, that improves vaccines durability and cross-protection in animal models. The protective efficacy of vaccine adjuvant Fos47 will be assessed in influenza virus challenge models to identify an optimal dosage, route and frequency of immunization. The vaccine adjuvant will be prepared in a large scale for the initiation of human clinical trials.